Page results
-
Our neonatal service is a recognised centre of excellence caring for acutely ill and preterm babies from our local area and beyond.
-
Neurosurgery is a treatment option for some people with epilepsy.
-
UCLH has been selected as the lead site in Great Britain for Neuralink’s GB-PRIME study, a clinical investigation for Neuralink’s brain-computer interface (BCI).
-
Advice on sleeping better for young people living with fatigue conditions.
-
This leaflet explains the support a transition coordinator at the Adolescent Rheumatology Department provides, and how they can help.
-
Information for patients and visitors on patient isolation.
-
This information is for patients, (and their family and carers), who are considering having Uterine Artery (Fibroid) Embolisation (UAE). It explains what is involved and the possible risks.
-
It is important to make sure you are eating and drinking well before your surgery. Good nutrition will also help you recover after your surgery.
-
A UCLH patient with a rare hormonal condition is the first in the world to receive a new investigational drug in a first-in-human trial.
-
Find & Treat's new prototype Eco-Tricycle will visit parks, hostels, soup kitchens, be able to arrive under bridges or other street outreach locations to screen homeless patients for infectious diseases and more.
File results
-
FOI/2022/0230 - Fabry, Gaucher and Pompe diseases drug treatments
-
FOI/2022/0232 - Number of patients who have died while waiting for elective care
-
FOI/2022/0233 - Diagnosis/ treatment of epilepsy, dravet syndrome, lennox gastaut syndrome and tuberous sclerosis complex
-
FOI/2022/0236 - Video communication software licences
-
FOI/2022/0238 - Number of mobile devices at Trust
-
FOI/2022/0244 - Craniocervical Instability assessment/ treatment
-
FOI/2022/0246 - Adult haematology services
-
FOI/2022/0247 - Care Axial SpA referrals to rheumatology
-
FOI/2022/0249 - Robotic process automation/ intelligent automation technology
-
FOI/2022/0250 - Number of staff employed and number of new patients diagnosed for breast, colorectal, head and neck and oesophageal cancer